Tomas
García-Caballero Parada
![Foto de Tomas](/img/nophoto.png)
![Foto de Hospital Vall d'Hebron](/img/noimage_org.png)
Hospital Vall d'Hebron
Barcelona, EspañaPublicacións en colaboración con investigadores/as de Hospital Vall d'Hebron (6)
2021
-
PD-L1 testing based on the SP142 antibody in metastatic triple-negative breast cancer: Summary of an expert round-table discussion
Future Oncology, Vol. 17, Núm. 10, pp. 1209-1218
2018
-
Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology
Clinical and Translational Oncology, Vol. 20, Núm. 7, pp. 815-826
-
Correction to: Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology (Clinical and Translational Oncology, (2018), 20, 7, (815-826), 10.1007/s12094-017-1800-5)
Clinical and Translational Oncology
2011
-
Consenso de la Sociedad Española de Anatomía Patológica (SEAP) y de la Sociedad Española de Oncología Médica (SEOM) sobre la determinación de HER2 en el carcinoma gástrico
Revista Espanola de Patologia, Vol. 44, Núm. 1, pp. 32-48
-
Consensus of the Spanish Society of Medical Oncology (SEOM) and Spanish Society of Pathology (SEAP) for HER2 testing in gastric carcinoma
Clinical and Translational Oncology, Vol. 13, Núm. 9, pp. 636-651
2009
-
Guidelines for HER2 testing in breast cancer. A national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Revista Espanola de Patologia, Vol. 42, Núm. 1, pp. 3-16